AVP-923
Sponsors
Avanir Pharmaceuticals, Otsuka Pharmaceutical Development & Commercialization, Inc.
Conditions
Alzheimer's DiseaseAmyotrophic Lateral SclerosisHealthyHealthy Adult Male and Female VolunteersHealthy VolunteerMultiple SclerosisParkinson's DiseaseStroke
Phase 1
Pharmacokinetics (PK) and Tolerability of AVP-786 in Healthy Volunteers
CompletedNCT01787747
Start: 2012-10-01End: 2013-02-01Updated: 2026-04-28
A Phase-1 Study to Assess the Pharmacokinetics, Safety and Tolerability of AVP-786 in Healthy Volunteers
CompletedNCT02174835
Start: 2013-09-01End: 2013-11-01Updated: 2026-04-28
A Phase 1 Study Comparing AVP-786 With AVP-923
CompletedNCT02336347
Start: 2014-05-01End: 2015-03-01Updated: 2026-04-28
Drug Interaction Study Between AVP-923 and Itraconazole and Between AVP-786 and Itraconazole in Healthy Adult Subejcts
CompletedNCT02402595
Start: 2015-03-01End: 2015-07-01Updated: 2026-04-28
Study to Assess the Bioavailability, Pharmacokinetics, Safety, and Tolerability of AVP-923 in Healthy Adult Participants
CompletedNCT03381664
Start: 2017-11-28End: 2018-01-30Updated: 2018-02-23
Phase 3
Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS
CompletedNCT00021697
Start: 2001-01-31End: 2002-04-30Target: 100Updated: 2016-07-14
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
CompletedNCT00050232
Start: 2002-12-31End: 2004-06-30Target: 96Updated: 2016-07-14
Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)
CompletedNCT00056524
Start: 2003-02-28End: 2007-06-30Target: 600Updated: 2016-07-14